Form 13-F position report

ENLIVEN THERAPEUTICS INC

Reported by Vestal Point Capital LP

ELVN CUSIP 29337E102 Manager CIK 0001974915

Reported 3,225,000 shares, down 775,000 (19.4%) from the prior quarter.

Reported value -27.2%; share count -19.4% vs. the prior quarter.

Reduced
% of reported 13F value 3.82% This manager · Q3 2026
Shares 3,225,000 Quarter-end amount reported
Reported value $147,834,000 Fair value at quarter end
Consecutive quarters held 6 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2025-06-30 5015000
2025-09-30 23745200
2025-12-31 58982000
2026-03-31 127400000
2026-06-30 203000000
2026-09-30 147834000

Quarterly position history

How this manager's reported quarter-end position changed over time.

6 quarters
Quarterly reported position history for ENLIVEN THERAPEUTICS INC held by Vestal Point Capital LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 3,225,000 -775,000 (-19.4%) 3.82% $147,834,000 2026-11-16
Q2 2026 Added 4,000,000 +750,000 (23.1%) 4.74% $203,000,000 2026-08-14
Q1 2026 Reduced 3,250,000 -580,000 (-15.1%) 3.56% $127,400,000 2026-05-15
Q4 2025 Added 3,830,000 +2,670,000 (230.2%) 2.01% $58,982,000 2026-02-17
Q3 2025 Added 1,160,000 +910,000 (364.0%) 1.07% $23,745,200 2025-11-14
Q2 2025 New 250,000 +250,000 (0.0%) 0.26% $5,015,000 2025-08-14

Who else reported the position

245 managers reported ENLIVEN THERAPEUTICS INC for Q3 2026.

Managers reporting ENLIVEN THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 10,827,727 +802,710 0.02% $496,343,006 15 qtrs
ORBIMED ADVISORS LLC Unchanged 6,776,632 0 5.67% $310,640,811 15 qtrs
Polar Capital Holdings Plc Reduced 6,425,271 -5,365 0.71% $294,534,423 10 qtrs
BlackRock Inc Added 5,711,966 +1,352,262 < 0.01% $261,836,522 9 qtrs
COMMODORE CAPITAL LP Unchanged 3,275,000 0 11.63% $150,126,000 15 qtrs
Vestal Point Capital LP This report Reduced 3,225,000 -775,000 3.82% $147,834,000 6 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 2,893,109 +324,107 < 0.01% $132,620,117 3 qtrs
PRICE T ROWE ASSOCIATES INC MD Reduced 2,350,207 -553,700 0.01% $107,735,000 10 qtrs
Fairmount Funds Management LLC Unchanged 1,855,644 0 5.33% $85,062,721 15 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 1,708,920 +301,718 < 0.01% $78,351,951 15 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
3,225,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.